Version 1
: Received: 15 August 2024 / Approved: 15 August 2024 / Online: 15 August 2024 (16:45:15 CEST)
How to cite:
Freile, B.; Rodriguez, A.; Catani, G.; Bortz, M.; Bruno, L.; O’Connor, J. M.; Esteso, F. Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer. Preprints2024, 2024081165. https://doi.org/10.20944/preprints202408.1165.v1
Freile, B.; Rodriguez, A.; Catani, G.; Bortz, M.; Bruno, L.; O’Connor, J. M.; Esteso, F. Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer. Preprints 2024, 2024081165. https://doi.org/10.20944/preprints202408.1165.v1
Freile, B.; Rodriguez, A.; Catani, G.; Bortz, M.; Bruno, L.; O’Connor, J. M.; Esteso, F. Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer. Preprints2024, 2024081165. https://doi.org/10.20944/preprints202408.1165.v1
APA Style
Freile, B., Rodriguez, A., Catani, G., Bortz, M., Bruno, L., O’Connor, J. M., & Esteso, F. (2024). Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer. Preprints. https://doi.org/10.20944/preprints202408.1165.v1
Chicago/Turabian Style
Freile, B., Juan Manuel O’Connor and Federico Esteso. 2024 "Targeted Therapies in Neoadjuvant Treatment for Gastroesophageal Cancer" Preprints. https://doi.org/10.20944/preprints202408.1165.v1
Abstract
Gastroesophageal cancers, are among the most prevalent cancers globally and represent the third leading cause of cancer-related mortality worldwide. Surgical resection remains the primary curative approach for localized and locally advanced stages, but its effectiveness is limited for locally advanced diseases, evidenced by a low 5-year survival rate of around 25%. High relapse rates post-surgery, particularly in western populations, necessitate the use of neoadjuvant, adjuvant, or perioperative strategies involving chemotherapy and radiation to improve surgical outcomes. Neoadjuvant chemoradiation therapy has demonstrated a significant improvement in overall survival. Recent advances have identified several target genes and pathways involved in the pathogenesis and progression of these cancers, leading to the development of targeted drugs, including immunotherapy, anti-HER-2 antibodies, and anti-VEGFR antibodies. These targeted therapies are emerging as promising interventions for better patient outcomes and personalized treatment approaches and therefore could eventually evolve into a novel therapeutic regimen for gastroesophageal cancer.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
